Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). It comprises the full 44-amino-acid GHRH sequence, an amidated C-terminus and a trans-3-hexenoyl group attached to the N-terminal tyrosine, giving a molecular weight of about 5.14 kilodaltons. In research it is studied as an agonist of the GHRH receptor, a G protein-coupled receptor on pituitary somatotrophs, and it is used to examine cyclic AMP signalling, growth hormone-axis biology, receptor pharmacology and the effect of N-terminal modification on peptide stability. This article covers its structure, mechanism, published laboratory findings, research applications, and the purity, storage and handling requirements for the material.
What is tesamorelin?
Tesamorelin, also known by the development code TH9507 and by the chemical name trans-3-hexenoyl-hGHRH(1-44)-NH2, is classified as a GHRH analogue. The native human GHRH(1-44) amide has the single-letter sequence YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL, with an amidated C-terminus. The analogue carries a six-carbon hexenoyl chain on the tyrosine at position 1. Its molecular formula is C221H366N72O67S and its mass is about 5,136 daltons, roughly 96 daltons more than the unmodified peptide. The single sulphur atom reflects the methionine at position 27, a residue that matters for oxidation, discussed below.
Native GHRH was isolated in 1982 from pancreatic tumours of patients with acromegaly by the groups of Roger Guillemin and Wylie Vale, and the 44-residue form was shown to be the full-length hormone. Work on the shorter fragments established that the first 29 residues retain activity, which led to the 29-residue analogue sermorelin. Longer analogues followed, and tesamorelin was developed as a stabilised full-length version. The N-terminal hexenoyl modification is intended to slow cleavage at the amino terminus, where native GHRH is degraded within minutes in plasma.
A regulatory point is worth stating at the outset. Tesamorelin is an authorised prescription medicine under a brand name in some jurisdictions. A medicine and a research reagent are different regulatory categories, even when the active substance is the same, and UK buyers should check the current position with the Medicines and Healthcare products Regulatory Agency. Nothing in this article concerns use in people.
Mechanism of action
Tesamorelin acts at the GHRH receptor, a class B member of the G protein-coupled receptor family. The receptor has seven transmembrane domains and is expressed predominantly in the anterior pituitary, on somatotroph cells. When the peptide binds, the receptor couples mainly to Gs, activating adenylyl cyclase and raising intracellular cyclic AMP. Cyclic AMP activates protein kinase A, which phosphorylates transcription factors such as CREB, and promotes calcium entry through voltage-gated channels. These signals stimulate transcription of the growth hormone gene and the release of stored hormone from the cell.
The pituitary-specific transcription factor Pit-1 is central to this pathway. It governs the development of somatotrophs, and the receptor is expressed in a pattern that parallels growth hormone gene expression. Signalling is opposed by somatostatin, which acts through Gi-coupled receptors on the same cells, so the output of the system in a pituitary culture reflects a balance of stimulatory and inhibitory inputs. The receptor is also regulated by desensitisation, through phosphorylation and internalisation, which shapes the response to prolonged exposure.
The distinguishing feature of tesamorelin is stability. Native GHRH is vulnerable to cleavage at its N-terminal Tyr-Ala sequence by dipeptidyl peptidase enzymes, and the hexenoyl group is intended to hinder that cleavage. A patent specification describing the analogue reported an in vitro half-life of three to eight hours compared with 0.56 hours for native GHRH, although patent data are not peer-reviewed and should be treated as indicative. For experimental purposes, the practical result is that the modified peptide persists longer in biological media, which affects incubation design and interpretation.
What the research shows
Four areas of published work underpin the use of GHRH analogues in the laboratory. Readers should consult the primary papers for methods and data.
The first is the 1992 cloning of the GHRH receptor by Kelly Mayo, published in Molecular Endocrinology. A cDNA was isolated from rat pituitary mRNA by PCR amplification of sequences encoding G protein-coupled receptors, and its human homologue was expressed in human kidney 293 cells, where membrane fractions bound human GHRH with high affinity and specificity. GHRH also stimulated intracellular cAMP production in the transfected cells, and the receptor mRNA was expressed predominantly, if not exclusively, in the anterior pituitary. The study defined the system that receptor-binding and cAMP assays still use, and the record is on PubMed.
The second is the work of Lin and colleagues, published in Nature in 1992, who cloned the receptor from mouse and rat. They reported a pituitary-restricted G protein-coupled receptor that mediates increases in intracellular cAMP and cAMP-dependent gene transcription in response to growth hormone-releasing factor, with an expression pattern that corresponds to growth hormone gene expression and is absent in Snell and Jackson dwarf mice carrying Pit-1 mutations. The paper links the receptor to somatotroph development and is available through Nature.
The third is early transgenic work by Mayo, Hammer and colleagues in 1988, which examined mice expressing a human growth hormone-releasing factor gene. The animals showed marked pituitary hyperplasia, a finding that demonstrated the proliferative influence of GHRH signalling on somatotrophs in a whole-animal model. It is summarised here in general terms, and readers should consult the original paper in Molecular Endocrinology for details.
The fourth is the structure-activity literature on GHRH analogues, including truncated, acylated and pegylated variants. These studies, carried out in receptor-expressing cell lines and animal models, established that the N-terminal residues make close contact with the receptor, that the first 29 residues are sufficient for activity, and that terminal modifications can change stability without abolishing agonism. They are described in general terms because the specific numbers vary with the assay and the analogue, and the primary papers should be consulted for any given comparison.
Research applications
Tesamorelin is used in several well-defined laboratory contexts. In receptor pharmacology, it serves as a stable agonist in binding and signalling assays on cell lines expressing the GHRH receptor, typically human embryonic kidney cells transfected with the receptor, where cyclic AMP accumulation is the usual readout. Its longer persistence compared with the native hormone makes it convenient for assays with extended incubations.
In primary pituitary cell cultures and pituitary-derived lines, it is applied to study growth hormone release, receptor desensitisation and interaction with somatostatin signalling. In studies of the wider growth hormone axis, researchers compare GHRH analogues with agonists of the ghrelin receptor, which acts through a separate GPCR, to examine whether the two signals interact in vitro.
In peptide chemistry and biophysics, tesamorelin is a model for examining how N-terminal acylation affects resistance to dipeptidyl peptidases, solution stability and aggregation of a 44-residue sequence. In analytical chemistry, it serves as a reference material for developing liquid chromatography and mass-spectrometry methods for larger peptides, where separating closely related impurities is demanding.
UK purchasers should also consider the regulatory framework. The MHRA decides case by case whether a product is a medicine, looking at labelling, packaging, promotional literature and advertisements, including websites. Its borderline products guidance explains the approach. Because the active substance is also an authorised medicine elsewhere, a research-use-only designation carries weight only when everything about how the material is supplied is consistent with laboratory use. This is general information, not legal advice, and institutions should involve their compliance staff.
Purity, storage and handling
At 44 residues, tesamorelin is a long synthetic peptide, and that has analytical consequences. Each coupling step in solid-phase synthesis is slightly less than perfectly efficient, so the longer the chain, the more deletion and truncated sequences accumulate, and these are structurally close to the target. Reversed-phase HPLC, usually with UV detection at 214 or 220 nm, separates the target from such by-products and reports purity as the percentage of total peak area belonging to the target. Because closely related impurities can co-elute, HPLC should be paired with mass spectrometry that confirms the observed mass of about 5,136 daltons and shows that the hexenoyl group is present, since the unmodified peptide is lighter by roughly 96 daltons.
A batch-specific certificate of analysis matters because synthesis is never perfectly repeatable. Two lots of the same sequence can differ in purity, counter-ion content, water content and net peptide content, and a generic specification sheet cannot capture that variation. A proper certificate lists the lot number, chromatogram, mass-spectrometry result and analysis date, so a result can be traced to a specific vial. Because a 44-residue peptide with a methionine and several asparagine residues is more prone to oxidation and deamidation than shorter sequences, batch-level HPLC verification matters more here than with simpler peptides. UK laboratories sourcing Tesamorelin should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and the supplier checks are set out in How to buy best peptides.
Lyophilised peptides are most stable when dry, sealed and cold. Storage at -20°C is the usual recommendation for the long term, and -80°C is sometimes preferred for sensitive sequences. Vials should be brought to room temperature in a desiccator before opening, because condensation introduces moisture that promotes hydrolysis. Oxidation of the methionine at position 27 adds 16 daltons and is detectable by mass spectrometry, so storage under inert gas is sensible for long-term holdings. Asparagine residues followed by small amino acids, such as the Asn-Ser pair near the N-terminus, are recognised hotspots for deamidation, which changes mass by about one dalton and may be hard to resolve without careful chromatography.
Reconstituted peptides are far less stable than the dry powder. Stock solutions are normally prepared in sterile water or a suitable buffer, divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Large peptides can aggregate or adsorb to surfaces, so low-binding tubes are advisable, and the solvent and pH should be selected with the sequence in mind. Stability in solution is sequence-specific, and researchers should consult supplier data and validate it under their own conditions.
Light sensitivity is a further consideration. Tesamorelin contains two tyrosines and aromatic residues that can undergo photo-oxidation, so vials are best stored in the dark or in amber glass, and bench exposure should be kept short. Each aliquot should be labelled with the date, lot number and concentration so that any later anomaly can be traced.
Frequently asked questions
What is tesamorelin’s molecular weight and sequence?
Tesamorelin is a 44-amino-acid analogue of human GHRH carrying a trans-3-hexenoyl group on the N-terminal tyrosine and an amidated C-terminus. Its molecular formula is C221H366N72O67S and its mass is about 5,136 daltons. Confirm identity of any batch against the certificate’s mass-spectrometry result.
Which receptor does tesamorelin act on?
It is an agonist at the GHRH receptor, a class B G protein-coupled receptor expressed mainly on anterior pituitary somatotrophs. In transfected cells, receptor activation raises intracellular cAMP through Gs coupling. Researchers measure it with cAMP accumulation, binding and growth hormone release assays in cell models.
How should lyophilised tesamorelin be stored?
Keep the sealed vial dry, protected from light and at -20°C for long-term storage. Allow it to reach room temperature in a desiccator before opening. Because the sequence contains methionine and asparagine residues, minimise air and moisture exposure, and divide reconstituted stock into single-use aliquots to avoid freeze-thaw cycles.
Is tesamorelin the same as sermorelin?
No. Both are GHRH analogues acting on the same receptor, but sermorelin is the 29-residue N-terminal fragment of GHRH, whereas tesamorelin is the full 44-residue sequence with an N-terminal hexenoyl group. They differ in length, mass, modification and stability, so analytical identity checks must distinguish them.
The compound discussed in this article is supplied for in-vitro laboratory research only and is not for human or veterinary use.